Business Standard

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Cipla, Cipla logo, Cipla headquarters
Premium

Cipla is the only generic player in the market and had launched the drug seven months earlier in February

Ram Prasad Sahu
The stock of pharma major Cipla was the biggest gainer in the Nifty Pharma and Healthcare indices, jumping about 5.5 per cent in trade on Tuesday. The Healthcare index also saw the largest increase among sectoral indices with a rise of about 3 per cent.

The Street is betting on a strong launch pipeline in the US, market share gains of recent launches and rising scale in the consumer business as some of the positives for the third-largest listed pharma entity.  

The company has captured a 9.3 per cent market share as of August in Lanreotide, a drug used in

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 20 2022 | 9:21 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com